The aim of this study is to evaluate whether there is a difference in the passage rate of the ureteral access sheath between patients who used mirabegron (a beta-3 receptor agonist) for overactive bladder and those who underwent retrograde intrarenal surgery for kidney stones, and those who did not use mirabegron. Considering that beta-3 receptors in the smooth muscle of the ureter cause relaxation in the ureter, the hypothesis that the passage rate of the access sheath increases in those using mirabegron, thus facilitating access to kidney stones and improving surgical success, will be investigated.

Inclusion Criteria:

• patients scheduled for RIRS due to kidney stones

Exclusion Criteria:

• preoperative ureteral stenting,
• ureteral strictures, history of ureteral or bladder surgery,
• anatomical abnormalities of the urinary tract,
• active urinary tract infection,
• pregnancy,
• uncontrolled hypertension (systolic blood pressure ≥180 mmHg, diastolic blood pressure ≥110 mmHg),
• use of medications affecting ureteral smooth muscle tone

patients scheduled for RIRS due to kidney stones

Due to patient confidentiality, this information can be shared with official permission.